Agenus Inc.
AGEN · NASDAQ
Market closed$5.01$0.010000 (+0.20%)After hours $5.02 · +0.20%
Key statistics
Previous close$5.00
Open$4.97
Day high$5.11
Day low$4.79
52-week high$8.70
52-week low$2.71
Market cap208.63M
Volume1.72M
Average volume3.90M
P/E ratio1.99
Forward P/E—
EPS2.52
Dividend yield0.00%
Market context
Why it moved
Despite AGEN's recent surge fueled by its oversubscribed $340 million private placement and positive clinical data for its botensilimab/balstilimab combination in cancer treatment, the stock is experiencing a modest pullback today as investors engage in profit-taking following a roughly 50% gain over the prior week.
What is happening
Recent company-specific developments and publisher coverage.
Simply Wall Street · July 17, 2026Agenus (AGEN) Is Up 54.3% After Oversubscribed US$340 Million Private Placement To Fund ROBBIN Trial – Has The Bull Case Changed?Stock Titan · July 17, 2026Agenus cancer combo spans colon cancer and sarcoma at ESMOInvesting.com · July 17, 2026Agenus abstracts on cancer drug combo accepted at ESMO 2026Seeking Alpha · July 15, 2026Agenus Surges 83% On $340 Million Financing: The Road To A 2030 Breakthrough (NASDAQ:AGEN)The Pharma Letter · July 15, 2026Agenus announces up to $340M funding to advance registrational ROBBIN trialCancerNetwork · July 14, 2026Agenus Discontinues Phase 3 BATTMAN Trial in Metastatic MSS Colorectal CancerOncodaily · July 13, 2026Agenus Announces Up to $340M Financing to Advance Phase 3 ROBBIN of Neoadjuvant BOT/BAL in MSS Colon CancerBusiness Wire · July 13, 2026Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer Benzinga · July 14, 2026Why Is Agenus Stock Falling on Tuesday? Benzinga · July 13, 2026Why Is Agenus Stock Gaining Monday? Benzinga · July 13, 2026Agenus Stock Soars Over 100% as BATTMAN Takes a Back Seat to ROBBIN Mt Newswire · July 13, 2026Agenus Signs Deal to Sell Up to $340 Million Worth of Securities; Shares Up Pre-Bell Benzinga · July 13, 2026Agenus To Raise $85M To Fund Colon Cancer Drug Trial, Financing Could Reach $340M If Warrants Are Exercised Mt Newswire · July 6, 2026Agenus' Potential Colorectal Cancer Combination Shows 21.2-Month Survival Benzinga · July 6, 2026Agenus Presents 3-Yr Landmark Phase 1b Data From Fully Enrolled C-800-01 Cohort Evaluating Botensilimab Plus Balstilimab In Patients With Refractory MSS mCRC Without Active Liver Metastases At ESMO GI 2026 Benzinga · June 25, 2026Agenus To Present 3-Yr Survival Data From Phase 1b C-800-01 Study Of Botensilimab Plus Balstilimab In Patients With Microsatellite Stable mCRC Without Active Liver Metastases At ESMO GI 2026